# EDGAR Filing Document

**Accession Number:** 0002065241
**File Stem:** 0000914190-26-000096
**Filing Date:** 2026-6
**Character Count:** 9878
**Document Hash:** e56b190b971d561980fe460a19bc347d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000914190-26-000096.hdr.sgml**: 20260604

**ACCESSION NUMBER**: 0000914190-26-000096

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260602

**FILED AS OF DATE**: 20260604

**DATE AS OF CHANGE**: 20260604

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Crouse Steven C.
- **CENTRAL INDEX KEY:** 0002065241

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-17272
- **FILM NUMBER:** 261065372

**MAIL ADDRESS:**
- **STREET 1:** 5980 HORTON STREET, STE 600
- **CITY:** EMERYVILLE
- **STATE:** CA
- **ZIP:** 94608
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BIO-TECHNE Corp
- **CENTRAL INDEX KEY:** 0000842023
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 411427402
- **STATE OF INCORPORATION:** MN
- **FISCAL YEAR END:** 0630

**BUSINESS ADDRESS:**
- **STREET 1:** 614 MCKINLEY PL N E
- **STREET 2:** SUITE 1500
- **CITY:** MINNEAPOLIS
- **STATE:** MN
- **ZIP:** 55413
- **BUSINESS PHONE:** 612-379-8854

**MAIL ADDRESS:**
- **STREET 1:** 614 MCKINLEY PLACE NE
- **CITY:** MINNEAPOLIS
- **STATE:** MN
- **ZIP:** 55413

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TECHNE CORP /MN/
- **DATE OF NAME CHANGE:** 19920703

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Crouse Steven C.<br><sub>(Last) (First) (Middle)</sub><br>614 MCKINLEY PLACE NE<br><sub>(Street)</sub><br>MINNEAPOLIS, MN 55413<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-06-02 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_President - Diag & Spatial Bi_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>BIO-TECHNE Corp [ TECH ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2026-06-02 |  | M |  | 600 | A | <sup>(1)</sup> | 6977<sup>(17)</sup> | D |  |
| Common Stock | 2026-06-02 |  | F |  | 216 | D | $49.77 | 6761 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Restricted Stock Units | <sup>(1)</sup> |  |  |  |  |  |  | <sup>(2)</sup> | <sup>(2)</sup> | Common Stock | 794 |  | 794 | D |  |
| Restricted Stock Units | <sup>(1)</sup> | 2026-06-02 |  | M |  |  | 600 | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock | 600 | $0 | 1200 | D |  |
| Restricted Stock Units | <sup>(1)</sup> |  |  |  |  |  |  | <sup>(4)</sup> | <sup>(4)</sup> | Common Stock | 1379 |  | 1379 | D |  |
| Restricted Stock Units | <sup>(1)</sup> |  |  |  |  |  |  | <sup>(5)</sup> | <sup>(5)</sup> | Common Stock | 3737 |  | 3737 | D |  |
| Restricted Stock Units | <sup>(1)</sup> |  |  |  |  |  |  | <sup>(6)</sup> | <sup>(6)</sup> | Common Stock | 6529 |  | 6529 | D |  |
| Stock Option (right to buy) | $97.13 |  |  |  |  |  |  | <sup>(7)</sup> | 2028-04-01 | Common Stock | 3856 |  | 3856 | D |  |
| Stock Option (right to buy) | $120.46 |  |  |  |  |  |  | <sup>(7)</sup> | 2028-08-06 | Common Stock | 19032 |  | 19032 | D |  |
| Stock Option (right to buy) | $94.52 |  |  |  |  |  |  | <sup>(8)</sup> | 2029-08-15 | Common Stock | 24560 |  | 24560 | D |  |
| Stock Option (right to buy) | $84.61 |  |  |  |  |  |  | <sup>(9)</sup> | 2030-08-15 | Common Stock | 12649 |  | 12649 | D |  |
| Stock Option (right to buy) | $73.46 |  |  |  |  |  |  | <sup>(10)</sup> | 2031-05-01 | Common Stock | 7327 |  | 7327 | D |  |
| Stock Option (right to buy) | $74.91 |  |  |  |  |  |  | <sup>(11)</sup> | 2034-08-15 | Common Stock | 17133 |  | 17133 | D |  |
| Stock Option (right to buy) | $48.61 |  |  |  |  |  |  | <sup>(12)</sup> | 2035-06-02 | Common Stock | 5434 |  | 5434 | D |  |
| Stock Option (right to buy) | $53.60 |  |  |  |  |  |  | <sup>(13)</sup> | 2035-08-15 | Common Stock | 19151 |  | 19151 | D |  |
| Performance Restricted Stock Units | <sup>(1)</sup> |  |  |  |  |  |  | <sup>(14)</sup> | <sup>(14)</sup> | Common Stock | 2387 |  | 2387 | D |  |
| Restricted Stock Units | <sup>(1)</sup> |  |  |  |  |  |  | <sup>(15)</sup> | <sup>(15)</sup> | Common Stock | 735 |  | 735 | D |  |
| Stock Option (right to buy) | $57.82 |  |  |  |  |  |  | <sup>(16)</sup> | 2036-03-02 | Common Stock | 1911 |  | 1911 | D |  |

---

### Footnotes:

(1) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.

(2) 794 restricted stock units vest on 5/1/2027.

(3) 600 restricted stock units vest on each of 6/2/2026, 6/2/2027 and 6/2/2028.

(4) 1,379 restricted stock units vest on 8/15/2026.

(5) 1,868 restricted stock units vest on 8/15/2026 and 1,869 restricted stock units vest on 8/15/2027.

(6) 2,176 restricted stock units vest on each of 8/15/2026 and 8/15/2028; and 2,177 restricted stock units vest on 8/15/2027.

(7) 100% vested.

(8) Options to purchase 6,140 shares vest on each of 8/15/2023, 8/15/2024, 8/15/2025 and 8/15/2026.

(9) Options to purchase 3,162 shares vest on each of 8/15/2024, 8/15/2026 and 8/15/2027; and options to purchase 3,163 shares vest on 8/15/2025.

(10) Options to purchase 1,832 shares vest on each of 5/1/2025, 5/1/2026 and 5/1/2028; and options to purchase 1,831 shares vest on 5/1/2027.

(11) Options to purchase 4,283 shares vest on each of 8/15/2025, 8/15/2027 and 8/15/2028; and options to purchase 4,284 shares vest on 8/15/2026.

(12) Options to purchase 1,359 shares vest on each of 6/2/2026 and 6/2/2028; and options to purchase 1,358 shares vest on each of 6/2/2027 and 6/2/2029.

(13) Options to purchase 4,788 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2029; and options to purchase 4,787 shares vest on 8/15/2028.

(14) Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

(15) 245 restricted stock units vest on 3/2/2027, 3/2/2028 and 3/2/2029.

(16) Options to purchase 478 shares vest on each of 3/2/2027, 3/2/2028 and 3/2/2030; and options to purchase 477 shares vest on 3/2/2029.

(17) Due to a mathematical error on the Form 4 filed May 5, 2026, the number of shares beneficially owned is being increased by 40 shares and this filing represents the correct number of shares beneficially owned by the Reporting Person.

**Signature:** /s/ Andrew Nick as Attorney-in-Fact for Steven C. Crouse pursuant to Power of Attorney previously filed.  
**Date:** 2026-06-04

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**